Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Renasight™ is a comprehensive, accessible renal genetics test for patients with chronic kidney disease. Learn more to help accelerate your research.
MDI Biological Laboratory
The MDI Biological Laboratory is a leading international research institution utilizing the most advanced scientific technology, artificial intelligence and nonmammalian models to develop new approaches for improving human health. Renowned for pioneering contributions to understanding renal physiology and function, MDI Biological Laboratory continues to play an important role in understanding the fundamental mechanisms of kidney damage and repair. MDI Bioscience now brings this expertise to drug development, collaborating with pharmaceutical companies to develop organoids and novel non-mammalian models to efficiently identify and characterize lead molecules. Our scientists develop tailored, disease-specific models for evaluating efficacy and toxicity in intact biological systems, complementing routine invitro screens and providing greater confidence in the future viability of early-stage molecules.
Newcells Biotech is a fast-growing team of global scientific and industry experts based in state-of-the-art facilities in the Helix Science Campus of Newcastle-upon-Tyne in the UK. Our purpose is to bridge the gap between scientific discovery and patients and we make a difference by providing better predictions of clinical outcomes. Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we build functional pre-clinical in vitro models of kidney, retina, liver and lung.
Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.
NIPOKA is a spin-off from the University Medicine Greifswald (Germany). We are the leading provider of morphological evaluations for glomerular research using super-resolution microscopy. All developed analyses provide reliable and reproducible results and can be optimized for high throughput. Our team has over 20 years of experience in podocyte research.
MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 275 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. Data readout of the TGFR Phase 3 Global Pivotal Study is expected in 2022.
Gubra is a privately held biotech located in Denmark delivering scientific counselling, contract research services, and projects for co-development in five main areas: Obesity, diabetes, NASH, kidney, and heart diseases. Gubra experts cover pre-clinical disciplines such as in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS, bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers.
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. George Clinical is known as the industry leading CRO for our innovative leadership in the kidney space. With more than 20 years of experience and 400 people managing 38 geographical locations throughout the USA, Asia-Pacific region, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials.
Nortis is advancing biology by bringing a new in-vitro standard to biomedical research and drug development. Organs-on-Chip is a rapidly emerging field in the life sciences market. Nortis' ParVivo system aims to provide powerful alternatives to the use of laboratory animals in the pharmaceutical industry and academic research. Our proximal tubule of the human kidney, has been shown to be more sensitive to drug side effects than animal kidneys